221 related articles for article (PubMed ID: 22298599)
21. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
[TBL] [Abstract][Full Text] [Related]
22. Newer insights into cisplatin nephrotoxicity.
Anand AJ; Bashey B
Ann Pharmacother; 1993 Dec; 27(12):1519-25. PubMed ID: 8305788
[TBL] [Abstract][Full Text] [Related]
23. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.
Meschi M; Detrenis S; Musini S; Strada E; Savazzi G
Crit Care Med; 2006 Aug; 34(8):2060-8. PubMed ID: 16763513
[TBL] [Abstract][Full Text] [Related]
24. Methods of reduction of cisplatin nephrotoxicity.
Walker EM; Gale GR
Ann Clin Lab Sci; 1981; 11(5):397-410. PubMed ID: 6277229
[TBL] [Abstract][Full Text] [Related]
25. [Can cisplatin renal toxicity be prevented?].
Brillet G; Deray G; Bunker D; Ben Hmida M; Baumelou A; Jacobs C
Nephrologie; 1991; 12(3):143-6. PubMed ID: 1922654
[TBL] [Abstract][Full Text] [Related]
26. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
27. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
[TBL] [Abstract][Full Text] [Related]
28. [Early phase II study of FK352 in cisplatin-induced nephropathy. Niigata Prefecture FK352 Study Group].
Yoshizawa H; Suzuki E; Arakawa M
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2085-94. PubMed ID: 9838911
[TBL] [Abstract][Full Text] [Related]
29. Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.
Morgan KP; Snavely AC; Wind LS; Buie LW; Grilley-Olson J; Walko CM; Weiss J
Ann Pharmacother; 2014 Jul; 48(7):863-869. PubMed ID: 24778426
[TBL] [Abstract][Full Text] [Related]
30. Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review.
Sikking C; Niggebrugge-Mentink KL; van der Sman ASE; Smit RHP; Bouman-Wammes EW; Beex-Oosterhuis MM; van Kesteren C
Oncologist; 2024 Feb; 29(2):e173-e186. PubMed ID: 37995306
[TBL] [Abstract][Full Text] [Related]
31. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity.
Ries F; Klastersky J
Am J Kidney Dis; 1986 Nov; 8(5):368-79. PubMed ID: 3538860
[TBL] [Abstract][Full Text] [Related]
32. A short outpatient hydration schedule for cisplatin administration.
Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
[TBL] [Abstract][Full Text] [Related]
33. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
Lee CK; Park KK; Hwang JK; Lee SK; Chung WY
Phytother Res; 2009 Jul; 23(7):999-1005. PubMed ID: 19140122
[TBL] [Abstract][Full Text] [Related]
34. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
[TBL] [Abstract][Full Text] [Related]
35. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
Ostrow S; Egorin MJ; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur NR; Wiernik PH
Cancer Treat Rep; 1981; 65(1-2):73-8. PubMed ID: 6784924
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of oral rehydration solution for hydration in cancer chemotherapy: toward the application of outpatient chemotherapy with high-dose Cisplatin therapy-].
Sato J; Kudo K; Hino K; Takahashi K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1471-6. PubMed ID: 21918344
[TBL] [Abstract][Full Text] [Related]
37. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
38. [Prevention and management of nephrotoxicity from anti-cancer agents].
Miyazaki J; Kawai K
Nihon Rinsho; 2003 Jun; 61(6):973-7. PubMed ID: 12806945
[TBL] [Abstract][Full Text] [Related]
39. Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial.
Murakami E; Akamatsu H; Shimokawa T; Wada K; Yamamoto N
BMJ Open; 2019 Dec; 9(12):e029057. PubMed ID: 31831529
[TBL] [Abstract][Full Text] [Related]
40. Reduction of cisplatin-induced nephrotoxicity by pyrazolone compounds, derivatives of tetrahydroindazolonedicarboxylic acid.
Marijic VF; Makarevic J; Stojkovic R; Kalinic L; Katalenic D; Radacic M
Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):675-80. PubMed ID: 19229375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
